David Margolis
Overview
Explore the profile of David Margolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
112
Citations
4488
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Watkins M, Zhu Y, Griffith D, Loutit J, Margolis D, Gu P
Antimicrob Agents Chemother
. 2024 Dec;
69(1):e0128824.
PMID: 39651882
BRII-693 is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic for infections caused by drug-resistant gram-negative pathogens. This single-center, randomized, double-blind, placebo-controlled phase 1 study investigated the safety, tolerability, and...
2.
Chew K, McGinley B, Moser C, Li J, Evering T, Ritz J, et al.
J Infect Dis
. 2024 Oct;
231(1):131-136.
PMID: 39400063
We explored viral and symptom rebound after coronavirus disease 2019 amubarvimab-romlusevimab monoclonal antibody therapy versus placebo in the randomized ACTIV-2/A5401 trial. Participants underwent nasal severe acute respiratory syndrome coronavirus 2...
3.
Evering T, Moser C, Jilg N, Ritz J, Wohl D, Li J, et al.
EClinicalMedicine
. 2024 Sep;
75:102787.
PMID: 39252866
Background: It is unknown if early COVID-19 monoclonal antibody (mAb) therapy can reduce risk of Long COVID. The mAbs amubarvimab/romlusevimab were previously demonstrated to reduce risk of hospitalization/death by 79%....
4.
Choudhary M, Deo R, Evering T, Chew K, Giganti M, Moser C, et al.
J Infect Dis
. 2024 May;
230(2):394-402.
PMID: 38716969
Background: Monoclonal antibodies (mAbs) represent a crucial antiviral strategy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but it is unclear whether combination mAbs offer a benefit over single-active...
5.
Salsabilian S, Lee C, Margolis D, Najafizadeh L
J Neural Eng
. 2024 Apr;
21(3).
PMID: 38621379
.This paper presents data-driven solutions to address two challenges in the problem of linking neural data and behavior: (1) unsupervised analysis of behavioral data and automatic label generation from behavioral...
6.
Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K, et al.
Pathog Immun
. 2024 Mar;
8(2):179-222.
PMID: 38505662
[This corrects the article DOI: 10.20411/pai.v8i2.665.].
7.
Harper J, Betts M, Lichterfeld M, Muller-Trutwin M, Margolis D, Bar K, et al.
Pathog Immun
. 2024 Mar;
8(2):115-157.
PMID: 38455668
Once a death sentence, HIV is now considered a manageable chronic disease due to the development of antiretroviral therapy (ART) regimens with minimal toxicity and a high barrier for genetic...
8.
Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, et al.
Am J Hematol
. 2024 Feb;
99(4):785-788.
PMID: 38343182
No abstract available.
9.
Giganti M, Chew K, Eron J, Li J, Pinilla M, Moser C, et al.
J Infect Dis
. 2023 Aug;
228(Suppl 2):S117-S125.
PMID: 37650230
Background: There is little information regarding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA as a predictor for clinical outcomes in outpatients with mild-to-moderate coronavirus disease 2019 (COVID-19). Methods: Anterior...
10.
Evering T, Chew K, Giganti M, Moser C, Pinilla M, Wohl D, et al.
Ann Intern Med
. 2023 Apr;
176(5):658-666.
PMID: 37068272
Background: Development of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life. Objective: To assess the safety and...